Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)

Vaccine

Volumn 32, Issue 50, 2014, Pages 6847-6854

  Minang, Jacob T ^a   Inglefield, Jon R ^a   Harris, Andrea M ^a   Lathey, Janet L ^a   Alleva, David G ^a   Sweeney, Diane L ^a   Hopkins, Robert J ^a   Lacy, Michael J ^a   Bernton, Edward W ^a  

^a Emergent Biosolutions   (United States)

Author keywords

Anthrax; BioThrax ; CPG 7909; Cytokine; T cell; Vaccine

Indexed keywords

AGATOLIMOD; ANTHRAX VACCINE; ANTHRAX VACCINE ADSORBED PLUS CPG 7909; ANTIGEN; C REACTIVE PROTEIN; EPITOPE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PEPTIDE; PLACEBO; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; CYTOKINE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; AMINO ACID SEQUENCE; ANTHRAX; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL IMMUNITY; BLOOD SAMPLING; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE RESPONSE; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; HYDROPHOBICITY; IN VITRO STUDY; INNATE IMMUNITY; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PILOT STUDY; POST EXPOSURE PROPHYLAXIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; VENOUS BLOOD; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; PROCEDURES; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; C-REACTIVE PROTEIN; CYTOKINES; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSPOT ASSAY; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES; VACCINATION;

EID: 84909578210     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.096     Document Type: Article

References (24)

1. ® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine 2011, 29(August (37)):6313-6320.
2. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Krieg A.M., Li Y., et al. Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques. Clin Vaccine Immunol 2008, 15(February (2)):221-226.
3. Krieg A.M., Efler S.M., Wittpoth M., Al Adhami M.J., Davis H.L. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004, 27(November (6)):460-471.
4. Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004, 22(August (23-24)):3136-3143.
5. Segura E., Villadangos J.A. Antigen presentation by dendritic cells in vivo. Curr Opin Immunol 2009, 21(February (1)):105-110.
6. Zent C.S., Smith B.J., Ballas Z.K., Wooldridge J.E., Link B.K., Call T.G., et al. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma 2012, 53(February (2)):211-217.
7. La Rosa C., Longmate J., Lacey S.F., Kaltcheva T., Sharan R., Marsano D., et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 2012, 205(April (8)):1294-1304.
8. Moseman E.A., Liang X., Dawson A.J., Panoskaltsis-Mortari A., Krieg A.M., Liu Y.J., et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+ CD25+ regulatory T cells. J Immunol 2004, 173(October (7)):4433-4442.
9. Kerkmann M., Rothenfusser S., Hornung V., Towarowski A., Wagner M., Sarris A., et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol 2003, 170(May (9)):4465-4474.
10. Vollmer J., Weeratna R., Payette P., Jurk M., Schetter C., Laucht M., et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004, 34(January (1)):251-262.
11. Rothenfusser S., Hornung V., Ayyoub M., Britsch S., Towarowski A., Krug A., et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood 2004, 103(March (6)):2162-2169.
12. Heijink I.H., Vellenga E., Borger P., Postma D.S., de Monchy J.G., Kauffman H.F. Interleukin-6 promotes the production of interleukin-4 and interleukin-5 by interleukin-2-dependent and -independent mechanisms in freshly isolated human T cells. Immunology 2002, 107(November (3)):316-324.
13. Kwok W.W., Yang J., James E., Bui J., Huston L., Wiesen A.R., et al. The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-specific CD4+ T cells with a phenotype distinct from that of naive PA T cells. Infect Immun 2008, 76(October (10)):4538-4545.
14. Hopkins R.J., Daczkowski N.F., Kaptur P.E., Muse D., Sheldon E., LaForce C., et al. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909) in healthy adult volunteers. Vaccine 2013, 31(June (30)):3051-3058.
15. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50(November (3-4)):213-219.
16. Singh H., Raghava G.P. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001, 17(December (12)):1236-1237.
17. Moodie Z., Price L., Gouttefangeas C., Mander A., Janetzki S., Löwer M., et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010, 59(October (10)):1489-1501.
18. García-de-Lorenzo A., Denia R., Atlan P., Martinez-Ratero S., Le Brun A., Evard D., et al. Parenteral nutrition providing a restricted amount of linoleic acid in severely burned patients: a randomised double-blind study of an olive oil-based lipid emulsion v. medium/long-chain triacylglycerols. Br J Nutr 2005, 94(August (2)):221-230.
19. Krieg A.M., Efler S.M., Wittpoth M., Al Adhami M.J., Davis H.L. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004, 27(November (6)):460-471.
20. Kang T.J., Fenton M.J., Weiner M.A., Hibbs S., Basu S., Baillie L., et al. Murine macrophages kill the vegetative form of Bacillus anthracis. Infect Immun 2005, 73(November (11)):7495-7501.
21. Gonzales C.M., Williams C.B., Calderon V.E., Huante M.B., Moen S.T., Popov V.L., et al. Antibacterial role for natural killer cells in host defense to Bacillus anthracis. Infect Immun 2012, 80(January (1)):234-242.
22. Crawford M.A., Burdick M.D., Glomski I.J., Boyer A.E., Barr J.R., Mehrad B., et al. Interferon-inducible CXC chemokines directly contribute to host defense against inhalational anthrax in a murine model of infection. PLoS Pathog 2010, 6(11):e1001199.
23. Klezovich-Bénard M., Corre J.P., Jusforgues-Saklani H., Fiole D., Burjek N., Tournier J.N., et al. Mechanisms of NK cell-macrophage Bacillus anthracis crosstalk: A balance between stimulation by spores and differential disruption by toxins. PLoS Pathog 2012, 8(January (1)):e1002481.
24. Speiser D.E., Liénard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005, 115(March (3)):739-746.